Vaxcyte, Inc. PCVX
63.83 USD +1.91 (+3.08%)
Nov 6, 2026, 11:30 AM EST
61.14 Day range 63.92
40.14 52-week range 90.75
- YTD
- +38.33%
- 1 year
- +53.02%
News
benzinga.com Vaxcyte Q3 EPS $(1.99) Beats $(2.12) Estimate Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.99) per share which beat the analyst consensus estimate of $(2.12) by 6.13 percent. This is a 27.56 percent decrease over losses of $(1.56) per…
globenewswire.com Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety Profile Similar…
zacks.com Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High? The mean of analysts' price targets for Vaxcyte (PCVX) points to an 87.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among…
benzinga.com Cantor Fitzgerald Reiterates Overweight on Vaxcyte, Announces $120 Price Target Cantor Fitzgerald analyst Carter Gould reiterates Vaxcyte (NASDAQ:PCVX) with a Overweight and announces $120 price target.
benzinga.com Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…' Stephen King slammed Trump’s incoming press secretary over her vaccine conspiracy theories and controversial posts.
benzinga.com A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally A new NIH-backed initiative to speed up personalized cancer vaccine development sent stocks like MRNA, BNTX, and NVAX surging Friday.
benzinga.com Crude Oil Edges Lower; Lamb Weston Shares Surge Following Upbeat Q1 Earnings U.S. stocks rose Tuesday: Dow +350 points, S&P 500 +0.86%. Lamb Weston jumped 12% on strong results; Arrivent plunged 58%.
benzinga.com Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Gain as Scott Bessent Doubles Down on Iran Pressure— OPCH, PCVX, STZ in Focus (UPDATED) U.S. stock futures were higher on Tuesday, as the Dow Jones, S&P 500 and Nasdaq 100 indices rose, following Monday's higher close.
benzinga.com Goosehead Insurance, Decent Holding And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures rose, while Goosehead fell after a downgrade; NFT, Armada and other stocks also slid in premarket trading.
benzinga.com Why Option Care Health Shares Are Trading Higher By Around 24%; Here Are 20 Stocks Moving Premarket Option Care Health jumped 23.8% on reports McKesson and CD&R may acquire it; Freight Technologies led gainers, while NFT Ltd. led decliners.
benzinga.com Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety Vaccine stocks are trending on Tuesday. Shares of Moderna Inc. (NASDAQ:MRNA), Vaxcyte Inc. (NASDAQ:PCVX) and Novavax Inc. (NASDAQ:NVAX) are moving in the after-hours session on Monday. Moderna rose…
benzinga.com Needham Maintains Buy on Vaxcyte, Raises Price Target to $122 Needham analyst Joseph Stringer maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $110 to $122.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers HeartBeam (NASDAQ:BEAT) stock moved upwards by 70.5% to $0.74 during Monday's regular session. The market value of their outstanding shares is at $24.4 million. PDS Biotechnology…
benzinga.com Dow Gains 100 Points; ISM Services PMI Falls In September U.S. stocks rose Monday: Dow +0.2%, S&P 500 +0.62%, Nasdaq +0.84%. Materials led; ISM services PMI slipped to 54.9. Oil fell 1%.
benzinga.com RXO, Vaxcyte, PTC And Other Big Stocks Moving Higher On Monday U.S. stocks mixed as Dow falls 250+ points; RXO surges 23% on $5.8B C.H. Robinson deal, while Vaxcyte and PTC post major gains.
benzinga.com Vaxcyte Stock Hits New 52-Week High - Here’s Why Vaxcyte announced positive Phase 3 OPUS-1 trial results for its VAX-31 vaccine candidate, setting the stage for an FDA BLA filing.
benzinga.com Guggenheim Maintains Buy on Vaxcyte, Raises Price Target to $125 Guggenheim analyst Seamus Fernandez maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $116 to $125.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Apimeds Pharmaceuticals (AMEX:APUS) stock moved upwards by 76.7% to $5.69 during Monday's pre-market session. The market value of their outstanding shares is at $4.8 million. Alector…- benzinga.com Vaxcyte Says Topline Results From OPUS-1 Pivotal Adult Phase 3 Trial Of VAX-31, a 31-valent Pneumococcal Conjugate Vaccine Candidate, Met All Prespecified Primary Endpoints Across Age Groups Studied Compared To Prevnar 20 And/Or Capvaxive VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20 (PCV20) and/or Capvaxive (PCV21)Prespecified Co-Primary Immunogenicity Endpoints: In Adults 50 and…
benzinga.com Alphabet To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Monday Analysts raised targets for Vertex and Okta, while cutting targets for McDonald’s, AutoZone, Vaxcyte and Camping World.- benzinga.com B of A Securities Maintains Buy on Vaxcyte, Lowers Price Target to $130 B of A Securities analyst Jason Gerberry maintains Vaxcyte (NASDAQ:PCVX) with a Buy and lowers the price target from $133 to $130.
benzinga.com Warren Buffett Disciple Seth Klarman Bets on Cruise Lines, Auto Parts, Amazon and Bill Ackman in Q2 Value investor Seth Klarman reveals his latest stock picks in a second quarter filing for hedge fund Baupost Group.
benzinga.com Vaxcyte Q2 EPS $(1.97) Beats $(2.22) Estimate Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.97) per share which beat the analyst consensus estimate of $(2.22) by 11.26 percent. This is a 61.48 percent decrease over losses of $(1.22) per…
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Top 3 Health Care Stocks You'll Regret Missing In May The health care sector's most oversold stocks are a buying opportunity due to undervalued companies. RSI indicator shows potential for short-term gains.
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com Vaxcyte Q1 EPS $(2.30) Misses $(1.82) Estimate Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(2.30) per share which missed the analyst consensus estimate of $(1.82) by 26.37 percent. This is a 121.15 percent decrease over losses of $(1.04)…
benzinga.com Vaxcyte Hits Enrollment Cap For Phase 3 Trials For VAX-31, A Pneumococcal Conjugate Vaccine Candidate Vaxcyte's next-generation 31-valent pneumococcal conjugate vaccine (PCV) candidate, for the prevention of invasive pneumococcal disease (IPD) and pneumonia in adults was finalized in consultation and…- benzinga.com Reported Earlier, Vaxcyte's VAX-31 Demonstrates Robust Immune Responses Across All 31 Serotypes In Lancet-Published Phase 1/2 Adult Study Versus Prevnar 20 Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data…
benzinga.com Nvidia To Rally More Than 53%? Here Are 10 Top Analyst Forecasts For Thursday 
benzinga.com BTIG Maintains Buy on Vaxcyte, Raises Price Target to $89 BTIG analyst Thomas Shrader maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $85 to $89.- benzinga.com Vaxcyte Q4 EPS $(1.80) Misses $(1.56) Estimate Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.80) per share which missed the analyst consensus estimate of $(1.56) by 15.38 percent. This is a 76.47 percent decrease over losses of $(1.02)…
- benzinga.com Earnings Scheduled For February 24, 2026
benzinga.com Earnings Outlook For Vaxcyte 
benzinga.com Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31; Company Expects To Report Topline Data From OPUS-3 Trial And OPUS-2 Phase 3 Trial Evaluating Concomitant Administration Of VAX-31 And A Seasonal Influenza Vaccine In First Half Of 2027 Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, today announced that the first participants were dosed in the OPUS-3 Phase 3 trial evaluating VAX-31, the Company's…- benzinga.com Vaxcyte Launches $500M Common Stock, Pre-Funded Warrants Offering Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced an underwritten public offering of $500,000,000 of its common stock and pre-funded…
benzinga.com Why Your Pneumonia Shot Is About To Get A Massive Upgrade Vaxcyte shares rise after starting Phase 3 trials for its VAX-31 pneumonia vaccine, expanding studies in adults and infants while planning major U.S. manufacturing investments.- benzinga.com Vaxcyte Advances VAX-31 Program With First Dosing In Adult Phase 3 OPUS-2 Trial; Plans Additional Phase 3 OPUS-3 Study In 2026; Completes Infant Phase 2 Enrollment VAX-31 Adult Indication: Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine (OPUS-2) and Expects to Initiate Phase 3…
benzinga.com CleanSpark, Cipher Mining, Bitdeer Technologies And Other Big Stocks Moving Lower In Monday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com Earnings Scheduled For February 25, 2025
- benzinga.com Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- benzinga.com Earnings Scheduled For February 27, 2024 Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023
- benzinga.com Earnings Scheduled For February 27, 2023 Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022 Upgrades
- benzinga.com Why Tricida Shares Dipped Around 95%; Here Are 73 Biggest Movers From Yesterday Gainers Applied Genetic Technologies Corporation (NASDAQ: AGTC) climbed 62.4% to close at $0.39. Syncona disclosed that it will acquire Applied Genetic Technologies Corporation.